Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.

Biochimica et biophysica acta - 1 Jun 2016

Fargue Sonia, Knight John, Holmes Ross P, Rumsby Gill, Danpure Christopher J

Abstract excerpt

The hereditary kidney stone disease primary hyperoxaluria type 1 (PH1) is caused by a functional deficiency of the liver-specific, peroxisomal, pyridoxal-phosphate-dependent enzyme, alanine:glyoxylate aminotransferase (AGT). One third of PH1 patients, particularly those expressing the p.[(Pro11Leu; Gly170Arg; Ile340Met)] mutant allele, respond clinically to pharmacological doses of pyridoxine. To gain further...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to CHO Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Hyperoxaluria, Primary

Share to Mutation

Share to Pyridoxine

Share to Reactive Oxygen Species

Share to Transaminases

Source

Open in PubMed Open full text

Identifiers

PMID: 26854734
DOI: 10.1016/j.bbadis.2016.02.004
PMCID: PMC5110007

Genes

AGT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay.PMID 26854734Read ↗

Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1.Semantic proximity Read ↗

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type ISemantic proximity Read ↗

Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I.Semantic proximity Read ↗

Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease.Semantic proximity Read ↗

Alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting in human hereditary kidney stone disease.Semantic proximity Read ↗

Liver peroxisomal alanine:glyoxylate aminotransferase and the effects of mutations associated with Primary Hyperoxaluria Type I: An overview.Semantic proximity Read ↗

Molecular etiology of primary hyperoxaluria type 1: new directions for treatment.Semantic proximity Read ↗

Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1.Semantic proximity Read ↗

Primary hyperoxalurias: disorders of glyoxylate detoxification.Semantic proximity Read ↗

[From gene to disease; primary hyperoxaluria type I caused by mutations in the AGXT gene].Semantic proximity Read ↗

Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria.Semantic proximity Read ↗

Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.